Search will undergo maintenance from 7pm EST on 4/22 to 5am EST on 4/23. Search will remain available, but results may vary.
Genetically engineered viruses capable of selectively targeting cancer cells while leaving healthy cells unharmed are gaining popularity as a promising oncolytic treatment. San Francisco-based biotech firm Jennerex debuted JX-594, a...
Contact us to learn the benefits of becoming a Lux member.
Or call us now
For North America (Boston Headquarters)
+1 (617) 502-5300
For EMEA (Amsterdam)
+31 20 280 7900
For APAC (Singapore)